Effects of Histone Deacetylase Inhibitor (Valproic Acid) on the Expression of Hypoxia-inducible Factor-1 Alpha in Human Retinal Müller Cells

키워드

참고문헌 (47)

1. Congdon N, "Causes a nd prevalence of visual impairment among adults in the United States", Arch Ophthalmol, 122, pp.477~485 (2004)
2. Congdon NG, "Important causes of visual impairment in the world today", JAMA, 290, pp.2057~2060 (2003)
3. Stalmans I, "Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms", J Clin Invest, 109, pp.327~336 (2002)
4. Haigh JJ, "Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling", Dev Biol, 262, pp.225~241 (2003)
5. Marneros AG, "Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function", Am J Pathol, 167, pp.1451~1459 (2005)
6. Aiello LP, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders", N Engl J Med, 331, pp.1480~1487 (1994)
7. Adamis AP, "Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy", Am J Ophthalmol, 118, pp.445~450 (1994)
8. Pierce EA, "Vascular endothelial growth factor", vascular permeability factor expression in a mouse model of retinal neovascularization, 1995, pp.92, 905~909
9. Miller JW, "Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy", Diabetes Metab Rev, 13, pp.37~50 (1997)
10. Aiello LP, "Hypoxic regulation of vascular endothelial growth factor in retinal cells", Arch Ophthalmol, 113, pp.1538~1544 (1995)
11. Stone J, "Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia", J Neurosci, 15(7 Pt 1), pp.4738~4747 (1995)
12. Stone J, "Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity", Invest Ophthalmol Vis Sci, 37, pp.290~299 (1996)
13. Bai Y, "Muller cell-derived VEGF is a significant contributor to retinal neovascularization", J Pathol, 219, pp.446~454 (2009)
14. Wang J, "Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage", Diabetes, 59, pp.2297~2305 (2010)
15. Kaelin WG Jr, "The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma", Clin Cancer Res, 13, pp.680s~684s (2007)
16. Liao D, "Hypoxia: a key regulator of angiogenesis in cancer", Cancer Metastasis Rev, 26, pp.281~290 (2007)
17. Ke Q, "Hypoxia-inducible f actor-1 (HIF-1)", Mol Pharmacol, 70, pp.1469~1480 (2006)
18. Pili R, "Is HIF-1 alpha a valid therapeutic target?", J Natl Cancer Inst, 95, pp.498~499 (2003)
19. Welsh SJ, "Hypoxia inducible factor as a cancer drug target", Curr Cancer Drug Targets, 3, pp.391~405 (2003)
20. Semenza GL, "Targeting HIF-1 for cancer therapy", Nat Rev Cancer, 3, pp.721~732 (2003)
21. Giaccia A, "HIF-1 as a target for drug development", Nat Rev Drug Discov, 2, pp.803~811 (2003)
22. Powis G, "Hypoxia inducible factor-1alpha as a cancer drug target", Mol Cancer Ther, 3, pp.647~654 (2004)
23. Brown JM, "Exploiting tumour hypoxia in cancer treatment", Nat Rev Cancer, 4, pp.437~447 (2004)
24. Poon E, "Targeting the hypoxia-inducible factor (HIF) pathway in cancer", Expert Rev Mol Med, 11, pp.e26~ (2009)
25. Gottlicher M, "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells", EMBO J, 20, pp.6969~6978 (2001)
26. Zhang ZH, "Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi1 leukemia cells", Mol Med Rep, 9, pp.443~449 (2014)
27. Shan Z, "Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo", Asian Pac J Cancer Prev, 13, pp.3977~3982 (2012)
28. Marks PA, "Histone deacetylase inhibitors as new cancer drugs", Curr Opin Oncol, 13, pp.477~483 (2001)
29. Drummond DC, "Clinical development of histone deacetylase inhibitors as anticancer agents", Annu Rev Pharmacol Toxicol, 45, pp.495~528 (2005)
30. Johnstone RW, "Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?", Cancer Cell, 4, pp.13~18 (2003)
31. DeNiro M, "Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy", Mol Pharmacol, 77, pp.348~367 (2010)
32. Adams JM, "HIF-1: a key mediator in hypoxia", Acta Physiol Hung, 96, pp.19~28 (2009)
33. Aiello LP, "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", Proc Natl Acad Sci U S A, 92, pp.10457~10461 (1995)
34. Rey S, "Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling", Cardiovasc Res, 86, pp.236~242 (2010)
35. Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
36. Yu F, "HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation", Proc Natl Acad Sci U S A, 98, pp.9630~9635 (2001)
37. Mie Lee Y, "Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity", Biochem Biophys Res Commun, 300, pp.241~246 (2003)
38. Williams RJ, "Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis", Expert Opin Investig Drugs, 10, pp.1571~1573 (2001)
39. Biermann J, "Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells", Invest Ophthalmol Vis Sci, 51, pp.526~534 (2010)
40. Zhang Z, "Valproic acid regulates antioxidant enzymes and prevents ischemia", reperfusion injury in the rat retina, 2012, pp.37, 429~437
41. Zhang Z, "Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation", Exp Eye Res, 94, pp.98~108 (2012)
42. Jeong JW, "Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation", Cell, 111, pp.709~720 (2002)
43. Kim MS, "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes", Nat Med, 7, pp.437~443 (2001)
44. Kong X, "Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha", Mol Cell Biol, 26, pp.2019~2028 (2006)
45. Qian DZ, "Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha", Cancer Res, 66, pp.8814~8821 (2006)
46. Lin M, "Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells", Diabetologia, 54, pp.1554~1566 (2011)
47. Mowat FM, "HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia", PLoS One, 5, pp.e11103~ (2010)

관련 논문AI추천